BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12855625)

  • 1. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.
    Iversen PL; Arora V; Acker AJ; Mason DH; Devi GR
    Clin Cancer Res; 2003 Jul; 9(7):2510-9. PubMed ID: 12855625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model.
    Sekhon HS; London CA; Sekhon M; Iversen PL; Devi GR
    Lung Cancer; 2008 Jun; 60(3):347-54. PubMed ID: 18096271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors.
    Devi GR; Beer TM; Corless CL; Arora V; Weller DL; Iversen PL
    Clin Cancer Res; 2005 May; 11(10):3930-8. PubMed ID: 15897595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
    Ko YJ; Devi GR; London CA; Kayas A; Reddy MT; Iversen PL; Bubley GJ; Balk SP
    J Urol; 2004 Sep; 172(3):1140-4. PubMed ID: 15311058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells.
    Devi GR; Oldenkamp JR; London CA; Iversen PL
    Prostate; 2002 Nov; 53(3):200-10. PubMed ID: 12386920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.
    London CA; Sekhon HS; Arora V; Stein DA; Iversen PL; Devi GR
    Cancer Gene Ther; 2003 Nov; 10(11):823-32. PubMed ID: 14605668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
    Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
    Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity.
    Arora V; Knapp DC; Smith BL; Statdfield ML; Stein DA; Reddy MT; Weller DD; Iversen PL
    J Pharmacol Exp Ther; 2000 Mar; 292(3):921-8. PubMed ID: 10688605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
    Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
    Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
    Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
    Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
    Chiu FL; Lin JK
    Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
    Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis.
    Singh RP; Sharma G; Dhanalakshmi S; Agarwal C; Agarwal R
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):933-9. PubMed ID: 14504208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.
    Gokhale PC; Zhang C; Newsome JT; Pei J; Ahmad I; Rahman A; Dritschilo A; Kasid UN
    Clin Cancer Res; 2002 Nov; 8(11):3611-21. PubMed ID: 12429653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction.
    Xiao D; Lew KL; Kim YA; Zeng Y; Hahm ER; Dhir R; Singh SV
    Clin Cancer Res; 2006 Nov; 12(22):6836-43. PubMed ID: 17121905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
    Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.